跳至主要内容
临床试验/NCT06334692
NCT06334692招募中不适用

Autoantibodies Against-nephrin in Idiopathic Nephrotic Syndrome

Mario Negri Institute for Pharmacological Research1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2024年3月19日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
100
试验地点
1
主要终点
Levels of circulating anti-nephrin autoantibodies

研究概览

简要总结

This retrospective study is aimed at evaluating the levels of circulating anti-nephrin autoantibodies in patients with INS, including those with MCD/FSGS and in patients who have experienced relapse of FSGS post-transplant, compared to those of a control group of patients with nephrotic syndrome due to primary membranous nephropathy (MN).

详细描述

Nephrotic syndrome (NS) is one of the major "unsolved problems" in nephrology and represents a long-standing challenge in terms of pathogenetic mechanisms and the search for an effective cure.

Nephrotic-range proteinuria (>3.5 g/day) is accompanied by a set of abnormalities collectively known as NS. It is characterized by systemic complications resulting from alterations in the composition of the body's protein pool, sodium retention, dyslipidemia, coagulation factor abnormalities and a variable degree of renal failure. When secondary causes cannot be identified, the clinical presentation is called idiopathic nephrotic syndrome (INS). INS is associated with disappearance of podocyte pedicels (visible under the electron microscope) and minimal changes (minimal change disease, MCD) or, at the more advanced stage, focal segmental glomerulosclerosis (FSGS) under the light microscope. INS can be treated with corticosteroids, which represent the first-line treatment, however, among the forms of NS, FSGS has the lowest rate of response to therapy. More importantly, in 30% of patients with FSGS, disease recurrence develops rapidly after transplantation, sometimes within minutes or hours, and leads to the immediate onset of proteinuria and graft dysfunction. For post-transplant FSGS recurrence, no prevention or treatment strategies are available and current therapeutic approaches are mostly based on clinical experience.

The recurrence of FSGS in the transplanted kidney presupposes the presence of one or more circulating factors of extrarenal origin which can selectively affect and damage the glomerular barrier, in particular the podocytes, resulting in massive proteinuria. However, the identity, nature and cellular source of factors circulating in the INS are not yet known.

Recent evidence of the therapeutic efficacy of anti-B cell antibodies in inducing and/or maintaining remission in patients with INS indicates the presence of possible B cell dysfunction.

In support of this, a recent study described the presence of anti-nephrin autoantibodies (a structural component of the podocyte slit diaphragm) in a subgroup of pediatric and adult patients with MCD. These autoantibodies were present during the active phase of the disease, and were associated with a punctate staining of IgG in renal biopsies in correspondence with the specific areas of presence of nephrin. Furthermore, the presence of autoantibodies against nephrin has been found in early post-transplant FSGS recurrence. This preliminary result was confirmed by a Japanese multicenter study conducted on 11 pediatric patients with post-transplant FSGS recurrence. In these patients, anti-nephrin autoantibodies were elevated both before transplantation and during disease relapse and were related to punctate deposition of immunoglobulins G (IgG) that colocalized with nephrin in the graft biopsy at the time of relapse. This recent evidence suggests that circulating anti-nephrin antibodies represent a possible circulating factor involved in the pathogenesis of INS, in particular post-transplant FSGS recurrence.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult (>18 years) males and females
  • Patients with biopsy-proven idiopathic MCD or FSGS (cases)
  • Patients with biopsy-proven idiopathic membranous nephropathy (controls)
  • Patients who provided consent to store their samples in the certified CRB biobank

排除标准

  • Reasonable possibility of a secondary cause of NS (for cases) or MN (for controls) at time of blood collections
  • Active viral or bacterial infections at time of blood collections

结局指标

主要结局

Levels of circulating anti-nephrin autoantibodies

时间窗: At 1 year. Given the retrospective nature of the study, the indicated time frame refers to the time required to perform the analysis, i.e to assess levels of anti-nephrin antibodies in patients with NS compared to controls.

Serum samples will be tested for the levels of anti-nephrin autoantibodies by in-house ELISA and results confirmed by commercial ELISA kits.

次要结局

未报告次要终点

研究者

发起方
Mario Negri Institute for Pharmacological Research
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验